1. Home /
  2. Biotechnology

Biotechnology

Exact Sciences Looks Vulnerable: Protect Longs

Exact Sciences Looks Vulnerable: Protect Longs

Shares of Exact Sciences has been on the upswing, but the stock price of the cancer screening test firm may be vulnerable.

Insider Buying Is Still Alive and Well at These 3 Companies

Insider Buying Is Still Alive and Well at These 3 Companies

Insider purchases have tapered off from their frenzied pace in late 2018, but here are three names where such buying is evident.

Stay Focused on Strong Defense Rather Than New Buys

Stay Focused on Strong Defense Rather Than New Buys

With market sentiment shifting it's time to protect capital until the action improves.

Activists Aim to Eliminate Dual Role for Allergan CEO Saunders

Activists Aim to Eliminate Dual Role for Allergan CEO Saunders

David Tepper's Appaloosa LP renews calls for changes at the top.

I Like the Long Side of Bristol-Myers Squibb

I Like the Long Side of Bristol-Myers Squibb

Let's see what the charts and indicators look like.

Allergan Rises After FDA Accepts License Applications for Botox Supplements

Allergan Rises After FDA Accepts License Applications for Botox Supplements

Allergan wants Botox licenses for pediatric patients.

Jim Cramer: No Room for Cynicism, JNJ's New Depression Drug Is Lifesaving

Jim Cramer: No Room for Cynicism, JNJ's New Depression Drug Is Lifesaving

The approval of esketamine, known as Spravato, for use against severe depression is special -- it is saving lives.

What to Expect from GE's Health Care Conference on Thursday

What to Expect from GE's Health Care Conference on Thursday

One of General Electric's biggest liabilities will be outlined on Thursday.

The Bears Now Have Possession of the Ball After Bulls Fumble It Away

The Bears Now Have Possession of the Ball After Bulls Fumble It Away

Can they finally put some points on the board?

Rules of Biotech Investing Change, and So Must Biotech Investors

Rules of Biotech Investing Change, and So Must Biotech Investors

One big change over the last few years has been the struggle of small concerns to penetrate mass markets even with approved and superior drugs.